Altamira Therapeutics Ltd. (CYTO) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Altamira Therapeutics Ltd. (CYTO) trades at $0.30 with AI Score 38/100 (Grade D). Altamira Therapeutics Ltd. Market cap: $1.13M, Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: May 31, 2026Analyst Coverage for CYTO: CYTO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CYTO against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CYTO: 3/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Altamira Therapeutics Ltd. (CYTO) Healthcare & Pipeline Overview
Altamira Therapeutics Ltd. is a biotechnology firm specializing in innovative therapeutics for inner ear disorders and extrahepatic RNA delivery. With a focus on addressing unmet medical needs, the company's portfolio includes a commercial nasal spray and clinical-stage assets targeting conditions like vertigo, tinnitus, and hearing loss across global markets.
What Is the Investment Thesis for CYTO?
Altamira Therapeutics presents a high-risk, high-reward investment profile characteristic of early-stage biotechnology companies. The company's value drivers include the successful clinical development and commercialization of its pipeline assets, particularly AM-125, Keyzilen, and Sonsuvi, which target significant unmet needs in vertigo, tinnitus, and hearing loss, respectively. Positive Phase III results for Keyzilen and Sonsuvi could serve as major catalysts. The advancement of its RNA delivery platforms, OligoPhore and SemaPhore, also represents a potential long-term value driver. However, the company's small market capitalization and limited financial resources pose significant risks, as does the inherent uncertainty of clinical trials. The company's beta of 2.44 indicates high volatility relative to the market.
Based on FMP financials and quantitative analysis
CYTO Key Highlights
- Bentrio is a commercially available drug-free nasal spray for personal protection against airborne viruses and allergens, providing an immediate revenue stream.
- AM-125 is in Phase II clinical trials for the intranasal treatment of vertigo, representing a potential breakthrough in a market with limited treatment options.
- Keyzilen is in Phase III clinical trials for the treatment of acute inner ear tinnitus, offering a potential solution for a condition affecting a significant portion of the population.
- Sonsuvi is in Phase III clinical development for the treatment of acute inner ear hearing loss, addressing a critical need in audiology.
- OligoPhore and SemaPhore platforms are in the preclinical stage for oligonucleotide and mRNA delivery, representing a long-term growth opportunity in RNA therapeutics.
Who Are CYTO's Competitors?
CYTO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.04 | -3.80% | $10.1M | 72 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.10 | +1.74% | $168M | 76 |
| CGEN Compugen Ltd. | $2.34 | -1.27% | $221M | 76 |
| NAGE Niagen Bioscience Inc | $3.37 | +2.74% | $268M | 69 |
| ORTX Orchard Therapeutics plc | $16.70 | +0.30% | $380M | 69 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| GNFTF Genfit S.A. | $10.75 | +0.00% | $539M | 73 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CYTO's Key Strengths?
- Innovative RNA delivery platforms.
- Diverse pipeline of clinical-stage assets.
- Commercial product (Bentrio) generating revenue.
- Experienced management team.
What Are CYTO's Weaknesses?
- Limited financial resources.
- High dependence on clinical trial outcomes.
- Small market capitalization.
- Limited commercial infrastructure.
What Could Drive CYTO Stock Higher?
- Results from Phase II clinical trials for AM-125 (vertigo treatment).
- Completion of Phase III clinical trials for Keyzilen (tinnitus treatment).
- Completion of Phase III clinical development for Sonsuvi (hearing loss treatment).
- Expansion of Bentrio's market reach and sales.
- Advancement of OligoPhore and SemaPhore RNA delivery platforms.
What Are the Key Risks for CYTO?
- Financial-distress signal — its Altman Z-Score of -1.16 sits in the distress zone (elevated bankruptcy risk).
- Failure of clinical trials for AM-125, Keyzilen, or Sonsuvi.
- Regulatory delays or rejection of marketing applications.
- Competition from other pharmaceutical companies.
- Limited financial resources to fund research and development.
- Economic downturn affecting healthcare spending.
What Are the Growth Opportunities for CYTO?
- Expansion of Bentrio's Market Reach: Bentrio, Altamira's drug-free nasal spray, presents a near-term growth opportunity through expanded distribution channels and geographic markets. The global market for nasal sprays is estimated at billions of dollars, with increasing demand for non-pharmaceutical options. By securing partnerships with major retailers and online platforms, Altamira can capitalize on the growing consumer interest in preventative healthcare and personal protection against airborne viruses and allergens. Timeline: Ongoing.
- Advancement of RNA Delivery Platforms: The OligoPhore and SemaPhore platforms represent a significant long-term growth opportunity for Altamira. These platforms are designed for the delivery of oligonucleotides and mRNA to extrahepatic targets, opening up possibilities for treating a wide range of diseases. Successful preclinical and clinical validation of these platforms could lead to partnerships with larger pharmaceutical companies. Timeline: 3-5 years.
- Successful Completion of Phase III Trials for Keyzilen: The successful completion of Phase III clinical trials for Keyzilen, a treatment for acute inner ear tinnitus, represents a major growth catalyst. Tinnitus affects a significant portion of the adult population, and there are limited effective treatments currently available. Positive trial results could lead to regulatory approval and commercial launch, generating substantial revenue for Altamira. The market for tinnitus treatments is estimated at hundreds of millions of dollars annually. Timeline: 1-2 years.
- Positive Outcomes from Phase II Trials for AM-125: The Phase II clinical trials for AM-125, an intranasal treatment for vertigo, are a crucial step towards addressing a significant unmet need. Vertigo affects millions of people worldwide, and current treatments often have limited efficacy or significant side effects. Positive trial results could position AM-125 as a novel and effective treatment option, driving significant growth for Altamira. The market for vertigo treatments is estimated at hundreds of millions of dollars annually. Timeline: 1-2 years.
- Strategic Partnerships and Licensing Agreements: Altamira can pursue strategic partnerships and licensing agreements to accelerate the development and commercialization of its pipeline assets. Collaborating with larger pharmaceutical companies can provide access to funding, expertise, and distribution networks. Licensing out certain assets can generate upfront payments and royalties, providing additional revenue streams. The biotechnology industry is characterized by frequent partnerships and acquisitions, creating opportunities for Altamira to enhance its value. Timeline: Ongoing.
What Opportunities Does CYTO Have?
- Strategic partnerships with larger pharmaceutical companies.
- Expansion of Bentrio's market reach.
- Successful clinical development of pipeline assets.
- Growing market for RNA therapeutics.
What Threats Does CYTO Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from established pharmaceutical companies.
- Economic downturn affecting healthcare spending.
What Are CYTO's Competitive Advantages?
- Proprietary RNA delivery platforms (OligoPhore and SemaPhore).
- Clinical-stage assets targeting unmet medical needs.
- Intellectual property protection for key products and technologies.
- Established presence in the inner ear therapeutics market.
What Does CYTO Do?
Altamira Therapeutics Ltd., founded in 2003 and headquartered in Hamilton, Bermuda, is a biotechnology company dedicated to developing therapeutics for unmet medical needs. Originally known as Auris Medical Holding Ltd., the company rebranded in July 2021 to reflect its expanded focus. Altamira's portfolio includes both commercial products and clinical-stage assets. A key commercial product is Bentrio, a drug-free nasal spray designed to provide personal protection against airborne viruses and allergens. The company is also advancing RNA therapeutics through its OligoPhore and SemaPhore platforms, which are currently in the preclinical stage and designed for oligonucleotide and mRNA delivery to extrahepatic targets. Clinical development programs include AM-125, an intranasal treatment for vertigo currently in Phase II trials; Keyzilen, in Phase III trials for acute inner ear tinnitus; and Sonsuvi, also in Phase III development for acute inner ear hearing loss. Altamira operates across multiple geographies, including Switzerland, the United States, Europe, and Australia, reflecting its global approach to addressing medical needs.
What Products and Services Does CYTO Offer?
- Develop therapeutics for unmet medical needs.
- Offer Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens.
- Develop RNA therapeutics for extrahepatic targets using OligoPhore and SemaPhore platforms.
- Conduct Phase II clinical trials for AM-125, an intranasal treatment for vertigo.
- Conduct Phase III clinical trials for Keyzilen, a treatment for acute inner ear tinnitus.
- Conduct Phase III clinical development for Sonsuvi, a treatment for acute inner ear hearing loss.
How Does CYTO Make Money?
- Develop and commercialize pharmaceutical products.
- Generate revenue through sales of Bentrio.
- Out-license technologies and products to other pharmaceutical companies.
- Seek partnerships for clinical development and commercialization.
What Industry Does CYTO Operate In?
Altamira Therapeutics operates within the biotechnology industry, a sector characterized by high innovation, long development cycles, and significant regulatory hurdles. The market for inner ear therapeutics, including treatments for tinnitus, vertigo, and hearing loss, is substantial and growing, driven by an aging population and increasing awareness of these conditions. Competition includes established pharmaceutical companies and other biotech firms developing novel therapies. Altamira's focus on RNA delivery platforms positions it within the rapidly expanding field of RNA therapeutics, which is attracting significant investment and attention.
Who Are CYTO's Key Customers?
- Individuals seeking protection against airborne viruses and allergens (Bentrio users).
- Patients suffering from vertigo (potential AM-125 users).
- Patients suffering from acute inner ear tinnitus (potential Keyzilen users).
- Patients suffering from acute inner ear hearing loss (potential Sonsuvi users).
F-Score 4/9Financial Health
Altamira Therapeutics Ltd.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -1.16 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on assets is -84.0%, showing how much profit it generates from its asset base. A current ratio of 1.32 indicates the company holds enough short-term assets to cover its near-term obligations.
Altamira Therapeutics Ltd. (CYTO) Valuation Context
Valued at $1.13M, CYTO is classified as a micro-cap stock. Relative to its peer group, CYTO's quantitative score of 38/100 is below the peer average of 73/100.
FY2026 estForward Outlook
Wall Street analysts project Altamira Therapeutics Ltd. revenue of about $6.3M for fiscal 2026, with EPS near $-1.44.
CYTO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, which can bolster investor sentiment.
- Community sentiment has shifted positively, with discussions highlighting the potential of Altamira's innovative therapies.
- Recent partnerships and collaborations have generated excitement, indicating strategic growth opportunities in the biotech space.
- Positive news coverage around clinical trial advancements has amplified interest, attracting more attention from retail investors.
Bear Case
- Market perception remains cautious due to the competitive landscape in the biotech sector, with many players vying for similar innovations.
- Recent volatility in stock performance has led to skepticism among some investors, creating a bearish outlook.
- Concerns about regulatory hurdles and the timeline for product approvals may dampen enthusiasm and investor confidence.
- Some community discussions reflect uncertainty regarding the company's long-term viability, leading to mixed sentiments among traders.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · February 2026
CYTO Latest News
No recent news available for CYTO.
CYTO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CYTO.
Price Targets
Wall Street price target analysis for CYTO.
CYTO MoonshotScore
What does this score mean?
The MoonshotScore rates CYTO 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Thomas Meyer
CEO
Thomas Meyer serves as the CEO of Altamira Therapeutics Ltd. His background includes extensive experience in the pharmaceutical and biotechnology industries, with a focus on strategic development and commercialization. He has held leadership positions in various companies, contributing to the advancement of innovative therapies. Meyer's expertise spans across drug development, regulatory affairs, and business development, making him instrumental in guiding Altamira's strategic direction and growth initiatives.
Track Record: Under Thomas Meyer's leadership, Altamira Therapeutics has focused on advancing its clinical pipeline, particularly the Phase III trials for Keyzilen and Sonsuvi. He has overseen the commercial launch of Bentrio and the development of the company's RNA delivery platforms. Meyer has also been involved in securing partnerships and funding to support the company's research and development efforts.
What Investors Ask About Altamira Therapeutics Ltd. (CYTO) — Healthcare
What does the AI Score mean for CYTO?
CYTO holds an AI Score of 38/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. Altamira Therapeutics Ltd. is a biotechnology company focused on developing therapeutics for unmet medical needs, including inner ear disorders and RNA delivery platforms. Their portfolio includes …
What does Altamira Therapeutics Ltd. do?
Altamira Therapeutics Ltd. is a biotechnology company focused on developing and commercializing innovative therapeutics to address significant unmet medical needs, particularly in the areas of inner ear disorders and RNA delivery. The company's portfolio includes Bentrio, a commercially available nasal spray, as well as clinical-stage assets such as AM-125 for vertigo, Keyzilen for tinnitus, and Sonsuvi for hearing loss.
What do analysts say about CYTO stock?
Given Altamira Therapeutics' small market capitalization and focus on clinical-stage assets, analyst coverage may be limited. However, analysts typically assess the company based on the potential of its pipeline assets, particularly AM-125, Keyzilen, and Sonsuvi. Key valuation metrics include the potential market size for these treatments, the probability of clinical trial success, and the likelihood of regulatory approval.
What are the main risks for CYTO?
The main risks for Altamira Therapeutics include the inherent uncertainties of clinical trials, as failure to achieve positive results for AM-125, Keyzilen, or Sonsuvi could significantly impact the company's value. Regulatory hurdles and potential delays in obtaining marketing approvals also pose risks. Additionally, the company faces competition from established pharmaceutical companies and other biotech firms.
What are the key factors to evaluate for CYTO?
Altamira Therapeutics Ltd. (CYTO) holds an AI score of 38/100 (low). Not financial advice.
How frequently does CYTO data refresh on this page?
CYTO's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CYTO's recent stock price performance?
Altamira Therapeutics Ltd. (CYTO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative RNA delivery platforms. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CYTO overvalued or undervalued right now?
Altamira Therapeutics Ltd. (CYTO) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CYTO before investing?
Before investing in Altamira Therapeutics Ltd. (CYTO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Clinical trial outcomes are inherently uncertain.